XBiotech Presents Phase III Findings for its Antibody Therapy for Colorectal Cancer at the 2017 ASCO Meeting
AUSTIN, Texas, June 01, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that data from XBiotech’s European Phase III Study of advanced colorectal cancer patients treated with Hutruo (MABp1) will be presented at the 2017 American …